Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Protein Manufacturing
Overview

 

Catalog Products
Online Store
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events

Case Studies

Spotlight
Generating sequence and functional diversity in transgenics
Generating sequence and functional diversity in transgenics
A case for genetic immunization
A case for genetic immunization
MHC I: A multi-cohort hybridoma workflow used to produce clinically relevant monoclonal antibodies
MHC I: A multi-cohort hybridoma workflow used to produce clinically relevant monoclonal antibodies
Developing highly specific mAb's – targeting post-translational modifications using Rabbit B cell Select
Developing highly specific mAb's – targeting post-translational modifications using Rabbit B cell Select

Posters

Spotlight
Bispecific antibody discovery and characterization: from discovery through production<br> 
Bispecific antibody discovery and characterization: from discovery through production
 
Humanization: rabbit mAb CDR grafting, the first step towards clinically suitable monoclonal antibodies
Humanization: rabbit mAb CDR grafting, the first step towards clinically suitable monoclonal antibodies
Seamless integration of AI technology into antibody development
Seamless integration of AI technology into antibody development

Webinars

Spotlight

Presenter: Dr. Ilse Roodink

Moderator: Dr. Debby Kruijsen

Presenter: Dr. Ilse Roodink

Presenter: Dr. Ilse Roodink

Presenter: Dr. Ilse Roodink

Moderator: Dr. Debby Kruijsen

Presenter: Dr. Ilse Roodink

Moderator: Dr. Debby Kruijsen

Presentations

Anti-idiotype antibodies – the superiority of Rabbit B cell Select

White Papers

icon notes

Transcript: Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics